The companies that had originally nominated the peptides for restriction withdrew their nominations, and on April 15, 2026 the FDA published the action, with the peptides coming off the Category 2 list effective April 22 to 23, 2026
Description A peptide liposomal tablet shown to offer therapeutic benefits that promote GI health and support reduced inflammation
Deficiency is common, especially in people who follow a vegetarian or vegan diets
Sikiric et al., 2020b), along with suggested significance of NO-synthase and the basal formation of NO in stomach mucosa, greater than that seen in other tissues (Whittle et al., 1992), BPC 157 exhibits a general, effective competing with both L-arginine analogs (i.e., L-NAME) and L-arginine (Sikiric et al., 2014)
In animal studies, AOD-9604 treatment reduced body weight gain by over 50% compared to controls over a 19-day period, with increased lipolytic activity in adipose tissue
Peptides are building blocks of proteins